DUBLIN, May 11, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Nano Chemotherapy Market & Clinical Trials Outlook 2022" report to their offering.
Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.
Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component.
The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.
Key Topics Covered:
1. Nano Chemotherapeutics Mediations - Solicitation to Nanomedicine
- Overview
- Nano Chemotherapeutics with Pharmaceutical Potential
2. Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
- Limitations of Conventional Chemotherapy
- Nanotechnology in Cancer Targeting
3. Role of Nanotherapeutics in Various Diseases Treatment
- Nanotherapeutics Approach for Cardiovascular Disease
- Nanotherapeutics Approach for Cancer Therapy
- Nanotherapeutics Approach for Diabetes Treatment
- Nanotherapeutics Approach for Rheumatoid Arthritis
4. Chemotherapeutics Nanoformulations of Approved Drugs: Clinical Insights & Price Analysis
- Abraxane (Advanced Lung, Pancreatic, Breast Cancers)
- Depocyte (Lymphomtous Meningitis)
- Doxil (Kaposi's Sarcoma, Ovarian Cancer)
- Marqibo (Acute Myelogenous Leukemia)
- Neulasta (Chemotherapy Induced Neutropenia)
- Oncospar (Acute Lymphoblastic Leukemia)
- Zevalin (Non-Hodgkin Lymphoma)
5. Chemotherapeutics Nanoformulations in Clinical Trials: Clinical Insight & Mode of Action
- MM-302 (Metastatic Breast Cancer)
- Thermodox (Hepatobiliary Tumors)
- CPX-351 (Acute Myelogenous Leukemia)
- IHL-305 (Solid Tumor Malignancy)
- MM-398 (Metastatic Pancreatic Cancer)
- BIND-014 (Metastatic Prostate Cancer)
- NK-012 (Solid Tumor Malignancy)
- CRLX-101 (Solid Tumor Malignancy & Rectal Cancer)
6. Global Market Nanotherapeutics Outlook
- Market Scenario of Nanotherapeutics
- Market Size of Nano-Medicines
7. Cancer Nanotherapeutics Market Revenue
- Sales of Nano-Chemotherapeutic Drugs
- Top Nanotherapeutics Companies Revenue
- Global Cancer Nanomedicine Clinical Pipeline Overview
8. Global Nano Chemotherapeutics Market Dynamics
- Favorable Parameters
- Challenges to the Market Growth
9. Future Perceptive of Nano Chemotherapeutics
10. Competitive Landscape
- Ablynx
- AMAG
- Amgen
- Celgene
- CytImmune
- Cornerstone
- Delpor
- Ensysce
- MagForce AG
- Merrimack
- Nanotherapeutics
- Nanobiotix
- Nanospectra
- Spectrum pharmaceuticals
- Tarveda
For more information about this report visit http://www.researchandmarkets.com/research/nvjznw/global_nano
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article